Heart Disease in Adult Syrian Refugees: Experience at Jordan University Hospital.
Adult
Aged
Aged, 80 and over
Cardiac Catheterization
/ statistics & numerical data
Cardiovascular Diseases
/ diagnosis
Charities
/ economics
Coronary Artery Disease
/ diagnosis
Diabetes Mellitus
/ diagnosis
Dyslipidemias
/ diagnosis
Female
Government Agencies
/ economics
Heart Valve Diseases
/ diagnosis
Hospitals, University
/ statistics & numerical data
Humans
Hypertension
/ diagnosis
Jordan
Lost to Follow-Up
Male
Middle Aged
Patient Acceptance of Health Care
/ statistics & numerical data
Percutaneous Coronary Intervention
/ statistics & numerical data
Refugees
/ statistics & numerical data
Retrospective Studies
Smoking
Syria
/ ethnology
Treatment Outcome
United Nations
/ economics
Young Adult
Journal
Annals of global health
ISSN: 2214-9996
Titre abrégé: Ann Glob Health
Pays: United States
ID NLM: 101620864
Informations de publication
Date de publication:
14 03 2019
14 03 2019
Historique:
entrez:
22
3
2019
pubmed:
22
3
2019
medline:
9
4
2020
Statut:
epublish
Résumé
Since 2011, 1.26 million Syrians have immigrated to Jordan, increasing demands on Healthcare service. Information about cardiovascular disease (CVD) in Syrian refugees in general, and specifically in Jordan, is unknown. The study aimed to describe CVD in Syrian refugee adults who were referred to Jordan University Hospital (JUH) in terms of diagnosis, presentation, outcome, sources of funding for treatment, and to follow these patients after their discharge. From January 2012 to October 2016, retrospective analysis was performed on the data of Syrian patients who were referred to JUH. This study describes the diagnoses, treatment, and outcome. It also discusses the funding sources; a follow-up was conducted until January 2017. There were 969 patients referred to JUH with CVD; median age was 56 years, 686 (72.2%) of them were males and 283 (27.8%) were females. Of the patients, 584 had hypertension (60%), 308 (31%) had diabetes mellitus, 281 (29.0%) suffered from dyslipidemia, and 237 were smokers (24%). There were 69.6% who had coronary artery disease (CAD) and 20 patients (2%) had valvular heart disease. Treatment was offered to 489 patients (49.5%), but only 322 (65.8% of treatment offered and 33.2% of referrals) of them received the intended treatment. Mortality rate was 3% and loss of follow-up was 49.2%. Funding for procedures mostly came from the Jordanian Health Aid Organization, the United Nations, NGOs, and charities. Sixty-four (13.3% of referred) patients were denied any funding during the time frame of this study. CVD is a major issue for both Syrian refugee patients and the Jordanian healthcare system. CAD and classic cardiovascular risk factors (specifically arterial hypertension, diabetes, and dyslipidemia) are most common in this specific population. Inadequate primary healthcare, suboptimal living conditions, lack of funding, and loss of patient contact are among the major challenges facing this vulnerable population.
Sections du résumé
BACKGROUND
Since 2011, 1.26 million Syrians have immigrated to Jordan, increasing demands on Healthcare service. Information about cardiovascular disease (CVD) in Syrian refugees in general, and specifically in Jordan, is unknown.
OBJECTIVES
The study aimed to describe CVD in Syrian refugee adults who were referred to Jordan University Hospital (JUH) in terms of diagnosis, presentation, outcome, sources of funding for treatment, and to follow these patients after their discharge.
METHODS
From January 2012 to October 2016, retrospective analysis was performed on the data of Syrian patients who were referred to JUH. This study describes the diagnoses, treatment, and outcome. It also discusses the funding sources; a follow-up was conducted until January 2017.
RESULTS
There were 969 patients referred to JUH with CVD; median age was 56 years, 686 (72.2%) of them were males and 283 (27.8%) were females. Of the patients, 584 had hypertension (60%), 308 (31%) had diabetes mellitus, 281 (29.0%) suffered from dyslipidemia, and 237 were smokers (24%). There were 69.6% who had coronary artery disease (CAD) and 20 patients (2%) had valvular heart disease. Treatment was offered to 489 patients (49.5%), but only 322 (65.8% of treatment offered and 33.2% of referrals) of them received the intended treatment. Mortality rate was 3% and loss of follow-up was 49.2%. Funding for procedures mostly came from the Jordanian Health Aid Organization, the United Nations, NGOs, and charities. Sixty-four (13.3% of referred) patients were denied any funding during the time frame of this study.
CONCLUSIONS
CVD is a major issue for both Syrian refugee patients and the Jordanian healthcare system. CAD and classic cardiovascular risk factors (specifically arterial hypertension, diabetes, and dyslipidemia) are most common in this specific population. Inadequate primary healthcare, suboptimal living conditions, lack of funding, and loss of patient contact are among the major challenges facing this vulnerable population.
Identifiants
pubmed: 30896135
doi: 10.5334/aogh.2474
pmc: PMC6634320
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2019 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/.
Déclaration de conflit d'intérêts
The authors have no competing interests to declare.
Références
PLoS One. 2016 Apr 13;11(4):e0150088
pubmed: 27073930
Scand J Public Health. 2001 Jun;29(2):140-50
pubmed: 11484867
Ann Glob Health. 2016 Mar-Apr;82(2):300-6
pubmed: 27372533
Ann Epidemiol. 2007 Sep;17(9):713-20
pubmed: 17553700
Int J Equity Health. 2016 Jul 14;15(1):108
pubmed: 27418336
Bull World Health Organ. 2013 Jun 1;91(6):394-5
pubmed: 24052674
BMJ. 2015 Aug 04;351:h4150
pubmed: 26243793
Int J Health Plann Manage. 2016 Jan-Mar;31(1):97-112
pubmed: 26799158
Int J Cardiol. 2006 Jun 16;110(2):179-83
pubmed: 16233922
Lancet. 2013 Jul 20;382(9888):206-7
pubmed: 23830357
BMC Public Health. 2015 Oct 31;15:1097
pubmed: 26521231